Ahngook Pharmaceutical and Sandoz Korea signed a joint sales agreement of asthma and COPD treatment inhaler 'Airflusal Forspiro'

On June 30, Ahngook Pharmaceutical and Sandoz Korea signed a joint sales agreement of asthma and COPD treatment inhaler 'Airflusal Forspiro'.

As a result, both Ahngook Pharmaceutical and Sandoz Korea will proceed with sales of 'Airflusal Forspiro' in general hospitals and clinics.

'Airflusal Forspiro' is an innovative inhaler which is a mixture salmeterol (long acting beta-2 agonist, LABA) an...